How fast was the business already accelerating?<\/p>\n
First, the engine was already redlining. As of its fiscal Q1 2025 report, the last one before the run, Lilly\u2019s revenue over the trailing twelve months<\/a> was up 36.4%. That wasn\u2019t just good; it was a sharp acceleration from its three-year average growth of 20.2%. The company\u2019s operating margin<\/a> for that quarter hit 40.2%, a world away from its 30.9% three-year average. The business wasn\u2019t just getting bigger; it was getting more profitable at a faster clip.<\/p>\n What was management pointing to next?<\/p>\n This is where it gets interesting. While investors were rightly focused on the blockbuster sales of injectable drugs like Mounjaro and Zepbound, management was already talking about the next act. On the May 2025 earnings call, when an analyst asked about a competitor gaining preferential treatment from a pharmacy benefit manager, the CEO\u2019s response was telling. He didn\u2019t just defend his current products. He pivoted.<\/p>\n \u201cOur focus is on making better medicines and more accessible medicines,\u201d he said, before immediately adding: \u201cSo our orforglipron is a topic today, excited by the possibility of an oral that could be more widely distributed.\u201d<\/p>\n He was answering a question about a competitive skirmish by pointing to a strategic game-changer: an oral GLP-1 pill. The company\u2019s stated goal was to create a medicine with \u201cinjectable GLP-1 like efficacy\u201d that could be \u201cmanufactured at scale to meet global demand.\u201d They were signaling that while everyone was watching the current battle, they were already building the next-generation portfolio differentiator.<\/p>\n Why was the company holding back on advertising?<\/p>\n The clearest tell, however, came from what the company wasn\u2019t doing. In late 2024, the finance chief explained that Lilly had been \u201cprudent scaling up and our demand-generation activities.\u201d In plain English: they were deliberately keeping a lid on marketing. Why? Because they were struggling to make enough product to satisfy the customers they already had.<\/p>\n The company then signaled it would \u201caccelerate demand activities\u201d into 2025 as supply caught up. It was a direct forecast of a growth inflection. The options market seemed to sense something was brewing, too. Just before the surge, implied volatility sat in the 85th percentile of its annual range, meaning traders were braced for a big move, though the direction was anyone\u2019s guess.<\/p>\n This was the sound of a company whose biggest challenge wasn\u2019t finding the next mountain to climb, but building a base camp big enough to support the expedition.<\/p>\n Not by listening harder; no individual can monitor thousands of companies that closely. The practical edge is to watch the one signal that is public and trackable: a guidance raise. Our Guidance Momentum rankings<\/a> show which S&P 500 names are flashing it now, with momentum to match. But guidance is one signal among many. The Trefis High Quality (HQ) Portfolio<\/a> weighs the full picture of quality across thousands of names, holds the 30 strongest, re-balances them with rules, and has outpaced a benchmark that combines the three major indices \u2013 the S&P 500, S&P Mid-cap, and Russell 2000.<\/p>\n","protected":false},"excerpt":{"rendered":"Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of,…\n","protected":false},"author":2,"featured_media":792280,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[73266,355798,64,63,355794,355796,355792,137,500,214072,220018,355793,355797,187823,355795],"class_list":["post-792279","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-abbv","tag-amgn","tag-au","tag-australia","tag-buy-lly","tag-compare-lly-stock","tag-eli-lilly-stock","tag-health","tag-healthcare","tag-jnj","tag-lly","tag-lly-stock","tag-mrk","tag-pfe","tag-sell-lly"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/792279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=792279"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/792279\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/792280"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=792279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=792279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=792279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/07\/pills-medicines-tablets-dose-rx-pharma-pharmaceutical-stockpack-pixabay.jpg\")
Photo by Rigby40 on Pixabay
\nHow Do You Get Ahead Of The Next One?<\/p>\n